HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C

被引：0

作者：

O'Loan, Joss ^{[1
,2
]}

Balcomb, Anne ^{[3
]}

Baker, David ^{[4
]}

Doyle, Joseph ^{[5
,6
]}

Godfrey, Daniel ^{[7
]}

Kozminsky, Michael ^{[8
]}

Mertens, Michael ^{[9
]}

Vanstraelen, Kim ^{[9
]}

Young, Matt ^{[1
,2
]}

机构：

[1] Med Clin, Inala, Australia

[2] Kombi Clin, Brisbane, Qld, Australia

[3] Prince St Clin, Orange, NSW, Australia

[4] East Sydney Doctors, Darlinghurst, NSW, Australia

[5] Alfred, Melbourne, Vic, Australia

[6] Monash Univ, Dept Infect Dis, Melbourne, Vic, Australia

[7] Gilead Sci Pty Ltd, Melbourne, Vic, Australia

[8] Genesis Med Ctr, Brighton, Australia

[9] Gilead Sci Ltd, London, England

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU419

引用

页码：S346 / S346

页数：1

共 50 条

[31] Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
Cheng, Pin-Nan
Mo, Lein-Ray
Chen, Chun-Ting
Chen, Chi-Yi
Huang, Chung-Feng
Kuo, Hsing-Tao
Lo, Ching-Chu
Tseng, Kuo-Chih
Huang, Yi-Hsiang
Tai, Chi-Ming
Peng, Cheng-Yuan
Bair, Ming-Jong
Chen, Chien-Hung
Yeh, Ming-Lun
Lin, Chih-Lang
Lin, Chun-Yen
Lee, Pei-Lun
Chong, Lee-Won
Hung, Chao-Hung
Chang, Te Sheng
Huang, Jee-Fu
Yang, Chi-Chieh
Hu, Jui-Ting
Lin, Chih-Wen
Wang, Chia-Chi
Su, Wei-Wen
Hsieh, Tsai-Yuan
Lin, Chih-Lin
Tsai, Wei-Lun
Lee, Tzong-Hsi
Chen, Guei-Ying
Wang, Szu-Jen
Chang, Chun-Chao
Yang, Sheng-Shun
Wu, Wen-Chih
Huang, Chia-Sheng
Chou, Kwok-Hsiung
Kao, Chien-Neng
Tsai, Pei-Chien
Liu, Chen-Hua
Lee, Mei-Hsuan
Cheng, Chien-Yu
Tsai, Ming-Chang
Liu, Chun-Jen
Dai, Chia-Yen
Lin, Han-Chieh
Kao, Jia-Horng
Chuang, Wan-Long
Yu, Ming-Lung
INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 485 - 500
[32] EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR (SOF/VEL) IN PATIENTS WITH CHRONIC HCV INFECTION AND PSYCHIATRIC DISORDERS: REAL-WORLD CARE MANAGEMENT FROM 6 COUNTRIES
Milligan, Scott
Barrett, Lisa
Teti, Elisabetta
Retortillo, Montserrat Garcia
Wedemeyer, Heiner
Fraser, Christopher
Amado, Luis Enrique Morano
Rodriguez-Tajes, Sergio
Acosta-Lopez, Silvia
O'Loan, Joss
Milella, Michele, Sr.
Ferrety, Maria Asuncion Buti
Veoz, Maria Guerra
Ramji, Anoor
Fernandez-Rodriguez, Conrado M.
Figueiredo, Luisa Martins
Fenech, Mary
Jimenez-Mutiloa, Elena
Macedo, Guilherme
Maida, Ivana
Ryan, Pablo
Campanale, Francesca
Bascia, Annalisa
Conway, Brian
Ranieri, Roberto
Borgia, Sergio Marcelo
De Ledinghen, Victor
Mangia, Alessandra
Mertens, Michael
Ntalla, Ioanna
Hernandez, Candido
Vanstraelen, Kim
Di Marco, Vito
HEPATOLOGY, 2020, 72 : 552A - 553A
[33] Real-world impact of a subsidy decision of sofosbuvir-velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes
Tan, Chee-Kiat
Luo, Xue-Shi
Ong, Benjamin Shao-Kiat
Lin, Liang
Ng, Kwong-Hoe
JGH OPEN, 2023, 7 (01): : 48 - 54
[34] HCV ELIMINATION IN HOMELESS PATIENTS IS POSSIBLE: A POOLED REAL-WORLD ANALYSIS OF HOMELESS PATIENTS WITH HCV TREATED WITH 12 WEEKS SOFOSBUVIR/VELPATASVIR (SOF/VEL)
Rodriguez-Tajes, Sergio
O'Loan, Joss
Retortillo, Montserrat Garcia
Perez, Francisco
Barrett, Lisa
Teti, Elisabetta
Ryan, Pablo
Fraser, Christopher
Veloz, Maria Guerra
Macedo, Guilherme
Amado, Luis Enrique Morano
De Ledinghen, Victor
Fenech, Mary
Martins, Alexandra
Mertens, Michael
Ntalla, Ioanna
Vanstraelen, Kim
Hernandez, Candido
Conway, Brian
HEPATOLOGY, 2020, 72 : 560A - 561A
[35] Real-World Effectiveness of Sofosbuvir/Velpatasvir/Voxilaprevir in 573 Treatment-Experienced Patients with Hepatitis C Genotypes 1 through 4
Belperio, Pamela S.
Shahoumian, Troy
Loomis, Timothy
Mole, Larry
Backus, Lisa I.
HEPATOLOGY, 2018, 68 : 142A - 142A
[36] Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients
Belperio, Pamela S.
Shahoumian, Troy A.
Loomis, Timothy P.
Backus, Lisa I.
JOURNAL OF VIRAL HEPATITIS, 2019, 26 (08) : 980 - 990
[37] Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting
Zarebska-Michaluk, Dorota
Jaroszewicz, Jerzy
Jakub, Klapaczynski
Sitko, Marek
Garlicki, Aleksander
Tudrujek, Magdalena
Tomasiewicz, Krzysztof
Belica-Wdowik, Teresa
Baka-Cwierz, Barbara
Pabjan, Pawel
Lorenc, Beata
Czauz-Andrzejuk, Agnieszka
Olga, Tronina
Krygier, Rafal
Dobracka, Beata
Orlowska, Iwona
Krzysztof, Simon
Dybowska, Dorota
Halota, Waldemar
Pawlowska, Malgorzata
Citko, Jolanta
Laurans, Lukasz
Mazur, Wlodzimierz
Piekarska, Anna
Janczewska, Ewa
Socha, Lukasz
Wawrzynowicz-Syczewska, Marta
Zbigniew, Deron
Berak, Hanna
Andrzej, Horban
Flisiak, Robert
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E249 - E250
[38] REAL-WORLD EFFECTIVENESS AND COST PER SUSTAINED VIRAL RESPONSE OF LEDIPASVIR/SOFOSBUVIR CHRONIC HEPATITIS C TREATMENT
Buggisch, P.
Wursthorn, K.
Stoehr, A.
Gauthier, A.
Atanasov, P. K.
Petersen, J.
JOURNAL OF HEPATOLOGY, 2016, 64 : S809 - S810
[39] Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan
Mizokami, Masashi
Liu, Lauren J.
Fujiyama, Naoto
Littman, Marcus
Yuan, Jason
Sekiya, Tomoko
Hedskog, Charlotte
Ng, Leslie J.
JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 129 - 141
[40] Effectiveness of 8-or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients
Curry, M. P.
Tapper, E. B.
Bacon, B.
Dieterich, D.
Flamm, S. L.
Guest, L.
Kowdley, K. V.
Lee, Y.
Milligan, S.
Tsai, N.
Younossi, Z.
Afdhal, N. H.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (05) : 540 - 548

← 1 2 3 4 5 →